These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 38615382)

  • 1. Comparative safety profile of bivalent and original COVID-19 mRNA vaccines regarding myocarditis/pericarditis: A pharmacovigilance study.
    Chen C; Chen C; Cao L; Fang J; Xiao J
    Int Immunopharmacol; 2024 May; 133():112022. PubMed ID: 38615382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Booster dose of COVID-19 mRNA vaccine does not increase risks of myocarditis and pericarditis compared with primary vaccination: New insights from the vaccine adverse event reporting system.
    Chen C; Fu F; Ding L; Fang J; Xiao J
    Front Immunol; 2022; 13():938322. PubMed ID: 36172346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada.
    Buchan SA; Seo CY; Johnson C; Alley S; Kwong JC; Nasreen S; Calzavara A; Lu D; Harris TM; Yu K; Wilson SE
    JAMA Netw Open; 2022 Jun; 5(6):e2218505. PubMed ID: 35749115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative assessment of myocarditis and pericarditis reporting rates related to mRNA COVID-19 vaccines in Europe and the United States.
    Hatziantoniou S; Anastassopoulou C; Lazaros G; Vasileiou K; Tsioufis C; Tsakris A
    Expert Rev Vaccines; 2022 Nov; 21(11):1691-1696. PubMed ID: 35815358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global estimates on the reports of vaccine-associated myocarditis and pericarditis from 1969 to 2023: Findings with critical reanalysis from the WHO pharmacovigilance database.
    Lee S; Jo H; Lee H; Lee H; Lee J; Kim HJ; Kang J; Jacob L; Smith L; Rahmati M; López Sánchez GF; Dragioti E; Jeon H; Cho JM; Choi Y; Park J; Woo S; Yon DK
    J Med Virol; 2024 Jun; 96(6):e29693. PubMed ID: 38859751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse Events Following COVID-19 Vaccination in Adolescents: Insights From Pharmacovigilance Study of VigiBase.
    Kim DH; Kim JH; Oh IS; Choe YJ; Choe SA; Shin JY
    J Korean Med Sci; 2024 Mar; 39(8):e76. PubMed ID: 38442719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review.
    Pillay J; Gaudet L; Wingert A; Bialy L; Mackie AS; Paterson DI; Hartling L
    BMJ; 2022 Jul; 378():e069445. PubMed ID: 35830976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: A self-controlled case series analysis in England.
    Stowe J; Miller E; Andrews N; Whitaker HJ
    PLoS Med; 2023 Jun; 20(6):e1004245. PubMed ID: 37285378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myocarditis and/or pericarditis risk after mRNA COVID-19 vaccination: A Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines.
    Abraham N; Spruin S; Rossi T; Fireman B; Zafack J; Blaser C; Shaw A; Hutchings K; Ogunnaike-Cooke S
    Vaccine; 2022 Jul; 40(32):4663-4671. PubMed ID: 35750537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myocarditis and pericarditis in adolescents after first and second doses of mRNA COVID-19 vaccines.
    Foltran D; Delmas C; Flumian C; De Paoli P; Salvo F; Gautier S; Drici MD; Karsenty C; Montastruc F
    Eur Heart J Qual Care Clin Outcomes; 2022 Mar; 8(2):99-103. PubMed ID: 34849667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myocarditis and pericarditis in individuals exposed to the Ad26.COV2.S, BNT162b2 mRNA, or mRNA-1273 SARS-CoV-2 vaccines.
    Pareek M; Sessa P; Polverino P; Sessa F; Kragholm KH; Sessa M
    Front Cardiovasc Med; 2023; 10():1210007. PubMed ID: 38075965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reports of myocarditis and pericarditis following mRNA COVID-19 vaccination: a systematic review of spontaneously reported data from the UK, Europe and the USA and of the scientific literature.
    Lane S; Yeomans A; Shakir S
    BMJ Open; 2022 May; 12(5):e059223. PubMed ID: 35613761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection.
    Patone M; Mei XW; Handunnetthi L; Dixon S; Zaccardi F; Shankar-Hari M; Watkinson P; Khunti K; Harnden A; Coupland CAC; Channon KM; Mills NL; Sheikh A; Hippisley-Cox J
    Nat Med; 2022 Feb; 28(2):410-422. PubMed ID: 34907393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of myocarditis and pericarditis following coronavirus disease 2019 messenger RNA Vaccination-A nationwide study.
    Su WJ; Liu YL; Chang CH; Lin YC; Huang WI; Wu LC; Chen SF; Lin YS; Hsieh YL; Yang CA; Lin CH; Chan KA; Lee PI; Chuang JH; Yang CH
    J Microbiol Immunol Infect; 2023 Jun; 56(3):558-565. PubMed ID: 36804307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study.
    Massari M; Spila Alegiani S; Morciano C; Spuri M; Marchione P; Felicetti P; Belleudi V; Poggi FR; Lazzeretti M; Ercolanoni M; Clagnan E; Bovo E; Trifirò G; Moretti U; Monaco G; Leoni O; Da Cas R; Petronzelli F; Tartaglia L; Mores N; Zanoni G; Rossi P; Samez S; Zappetti C; Marra AR; Menniti Ippolito F;
    PLoS Med; 2022 Jul; 19(7):e1004056. PubMed ID: 35900992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Risk of Myocarditis/Pericarditis Following Second Doses of BNT162b2 and mRNA-1273 Coronavirus Vaccines.
    Naveed Z; Li J; Wilton J; Spencer M; Naus M; Velásquez García HA; Kwong JC; Rose C; Otterstatter M; Janjua NZ;
    J Am Coll Cardiol; 2022 Nov; 80(20):1900-1908. PubMed ID: 36357091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Features of Inflammatory Heart Reactions Following mRNA COVID-19 Vaccination at a Global Level.
    Chouchana L; Blet A; Al-Khalaf M; Kafil TS; Nair G; Robblee J; Drici MD; Valnet-Rabier MB; Micallef J; Salvo F; Treluyer JM; Liu PP
    Clin Pharmacol Ther; 2022 Mar; 111(3):605-613. PubMed ID: 34860360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial.
    Lee IT; Cosgrove CA; Moore P; Bethune C; Nally R; Bula M; Kalra PA; Clark R; Dargan PI; Boffito M; Sheridan R; Moran E; Darton TC; Burns F; Saralaya D; Duncan CJA; Lillie PJ; San Francisco Ramos A; Galiza EP; Heath PT; Girard B; Parker C; Rust D; Mehta S; de Windt E; Sutherland A; Tomassini JE; Dutko FJ; Chalkias S; Deng W; Chen X; Feng J; Tracy L; Zhou H; Miller JM; Das R;
    Lancet Infect Dis; 2023 Sep; 23(9):1007-1019. PubMed ID: 37348519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5-11 Years - United States, October 12-January 1, 2023.
    Hause AM; Marquez P; Zhang B; Su JR; Myers TR; Gee J; Panchanathan SS; Thompson D; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(2):39-43. PubMed ID: 36634021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents.
    Karlstad Ø; Hovi P; Husby A; Härkänen T; Selmer RM; Pihlström N; Hansen JV; Nohynek H; Gunnes N; Sundström A; Wohlfahrt J; Nieminen TA; Grünewald M; Gulseth HL; Hviid A; Ljung R
    JAMA Cardiol; 2022 Jun; 7(6):600-612. PubMed ID: 35442390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.